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 GLOSSARY 
Family history A family history of disease in an individual is the occurrence of the disease in a blood relative of that individual. 
Gene A gene is a molecular unit of heredity of a living organism. 
Genetic counselling A service delivered by a qualified health professional that provides a comprehensive evaluation of familial risk for 
inherited disorders using kindred analysis and other methods, patient education, discussion of the benefits and harms 
of genetic testing, interpretation of results after testing (consequences and nature of the disorder, probability of 
developing or transmitting it), and discussion of management options. 
Genetic counsellor A healthcare professional providing individuals and families with information on the nature, inheritance, and implications 
of genetic disorders to help them make informed medical and personal decisions. If it is appropriate, they will discuss 
genetic testing, coordinate any testing, interpret test results, and review all additional testing, surveillance, surgical, or 
research options that are available to members of the family. 
Genetic testing Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a 
genetic test can confirm or rule out a suspected genetic condition or help determine a person’s chance of developing or 
passing on a genetic disorder. 
Germline  The cells from which eggs or sperm (i.e., gametes) are derived. 
Penetrance A characteristic of a genotype; it refers to the likelihood that a clinical condition will occur when a particular genotype is 
present. 
Relatives – First-degree relatives These are the closest blood relatives (relatives by marriage do not count). These include father, mother, son, daughter, 
brother, sister. 
Relatives – Second-degree 
relatives 
These are blood related grandparents, grandchildren, uncle, aunt, nephews and nieces, half-brothers and half-sisters. 
They are on both the mother and father’s side of the family. 
Relatives – Third-degree relatives These are blood related great grandparents, great grandchildren, great uncle, great aunt, first cousin, grand-nephew and 
grand-niece. They are on both the mother and father’s side of the family. 
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LIST OF 
ABBREVIATIONS  
 
ABBREVIATION DEFINITION 
ARF Alternate Reading Frame 
ASCO American Society of Clinical Oncology 
BHD Birt-Hogg-Dubé syndrome 
CDK4 Cyclin-dependent kinase 4 
CDKN2A Cyclin-dependent kinase inhibitor 2A 
CT Computed Tomography 
DELM Digital Epiluminescence Microscopy  
ELM Epiluminescence Microscopy  
FAMM Familial atypical multiple mole melanoma syndrome 
FLCN Folliculin 
GDG Guideline Development Group  
genoMEL Melanoma genetics consortium 
HADS  Hospital Anxiety and Depression Scale  
JMML Juvenile myelomonocytic leukemia  
MC1R  Melanocortin 1 receptor 
MeSH Medical Subject Headings 
MRI Magnetic Resonance Imaging 
NF1 Neurofibromatosis 1 
NF2 Neurofibromatosis 2 
NIH National Institutes of Health  
NIHDI (RIZIV/INAMI) National Institute for Health and Disability Insurance 
NNFF National Neurofibromatosis Foundation 
PICO Population Intervention Control Outcome 
RCT Randomised controlled trial 
SPRED1 SProuty-Related, EVH1 Domain containing 1 
SR/MA Systematic reviews and meta-analyses 
SSE Skin Self Examination  
VS Vestibular Schwannomas 
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 SCIENTIFIC REPORT 
                                                     
a  In addition, a reimbursement is foreseen for tests performed abroad (if no 
Belgian specialised laboratory is able to perform the test) for diagnostic 
1 INTRODUCTION 
1.1 Background 
This guideline treats the Birt-Hogg-Dubé syndrome, the familial atypical 
multiple mole melanoma syndrome and neurofibromatosis 1&2. These 
syndromes only have in common that dermatological manifestations are 
involved, but implications, risks and issues around testing and follow-up are 
very diverse. A specific background will be given for each syndrome 
separately. 
1.2 The need for a guideline 
Criteria are needed for the identification and referral of patients to genetic 
centres for counselling, possibly followed by germline mutation analysis. It 
is important to provide such guidance to all clinicians active in the field. This 
guideline is timely because the new nomenclature, introduced on 1/1/2013, 
for genetic tests (article 33) and the agreement on genetic testing 
consultation led to distribute the NIHDI budget between genetic counselling 
(€4,288 millions) and laboratory procedures (€37,795 millions)a. There is a 
need to standardise the use of these tests and base their use on available 
evidence. Early identification of persons at risk makes the initiation 
strategies possible that may reduce morbidity or be lifesaving, including 
enhanced surveillance and surgery. It may also help the patient in making 
decisions concerning preconception and antenatal screening and 
reproduction in general.  
This clinical practice guideline is based on the collaborative efforts of the 
Belgian Health Care Knowledge Centre (KCE), the College of Human 
Genetics and the College of Oncology. This guideline is the fourth report in 
a short series of oncogenetic testing guidelines. 
  
analysis of DNA samples from patients (and their relatives) suffering from rare 
cancers or rare diseases. 
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1.3 Scope 
This guideline will cover following populations: 
 Persons considered at risk based on clinical suspicion or family history. 
This guideline will cover following issues: 
 Who has to undergo genetic tests; 
 Tests for which genes have clinical utility; 
 What follow-up is recommended depending on test results and family 
history. 
The guideline will not cover treatment of patients, including surgery. 
1.4 Remit of the guideline 
1.4.1 Overall objectives 
This guideline provides recommendations based on current scientific 
evidence for the diagnosis and follow-up of patients with clinical suspicion 
of Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma 
syndrome and neurofibromatosis 1&2. Clinicians are encouraged to 
interpret these recommendations in the context of the individual patient 
situation, values and preferences.  
All KCE guidelines are based on clinical evidence and may not always be in 
line with the current criteria for NIHDI (RIZIV/INAMI) reimbursement of 
diagnostic and therapeutic interventions. The NIHDI may consider 
adaptation of reimbursement/funding criteria based on these guidelines. 
1.4.2 Target users of the guideline 
This guideline is intended to be used by care providers involved in genetic 
counselling, testing and follow-up of patients with Birt-Hogg-Dubé 
syndrome, familial atypical multiple mole melanoma syndrome and 
neurofibromatosis 1&2. It also contains recommendations for persons that 
must decide when to refer for genetic counselling and testing such as 
general practitioners, paediatricians, dermatologists or surgeons, 
radiologists and pathologists. 
1.5 Statement of intent 
Clinical Guidelines are designed to improve the quality of health care and 
decrease the use of unnecessary or harmful interventions. This guideline 
has been developed by clinicians and researchers for use within the Belgian 
healthcare context. It provides advice regarding the care and management 
of patients with Birt-Hogg-Dubé syndrome, familial atypical multiple mole 
melanoma syndrome and neurofibromatosis 1&2. 
The recommendations are not intended to indicate an exclusive course of 
action or to serve as a standard of care. Standards of care are determined 
on the basis of all the available clinical data for an individual case and are 
subject to change as scientific knowledge and technology advance and 
patterns of care evolve. Variations, which take into account individual 
circumstances, clinical judgement and patient choice, may also be 
appropriate. The information in this guideline is not a substitute for proper 
diagnosis, treatment or the provision of advice by an appropriate health 
professional. It is advised, however, that significant deviations from the 
national guideline are fully documented in the patient’s file at the time the 
relevant decision is taken. 
1.6 Funding and declaration of interest 
KCE is a federal institution funded for the largest part by INAMI/RIZIV, but 
also by the Federal Public Service of Health, Food chain Safety and 
Environment, and the Federal Public Service of Social Security. The 
development of clinical practice guidelines is part of the legal mission of the 
KCE. Although the development of guidelines is paid by KCE’s budget, the 
sole mission of the KCE is providing scientifically valid information. KCE has 
no interest in companies (commercial or non-commercial i.e. hospitals and 
universities), associations (e.g. professional associations, unions), 
individuals or organisations (e.g. lobby groups) that could be positively or 
negatively affected (financially or in any other way) by the implementation of 
these guidelines. All clinicians involved in the Guideline Development Group 
(GDG) or the peer-review process completed a declaration of interest form. 
Information on potential conflicts of interest is published in the colophon of 
this report. All members of the KCE Expert Team make yearly declarations 
of interest and further details of these are available upon request. 
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2 METHODOLOGY 
2.1 Introduction 
This guideline was developed using a standard methodology based on a 
systematic review of the evidence. Further details about KCE and the 
guideline development methodology are available at 
https://kce.fgov.be/content/kce-processes. 
Several steps were followed to elaborate this guideline. Firstly, clinical 
questions were developed and the inclusion and exclusion criteria were 
defined in collaboration with members of the Guideline Development Group. 
Secondly, a literature review was conducted (including a search for recent, 
high quality guidelines). Thirdly, on the basis of the results of the literature 
review, recommendations were formulated. 
2.2 The Guideline Development Group 
This guideline was developed as a result of a collaboration between 
multidisciplinary groups of practising clinicians and KCE experts. The 
composition of the GDG is documented in the colophon. Guideline 
development and literature review expertise, support, and facilitation were 
provided by the KCE Expert Team.  
The roles assigned to the GDG were:  
 To define the clinical questions, in close collaboration with the KCE 
Expert Team and stakeholders;  
 To identify critical and important outcomes; 
 To provide feedback on the selection of studies and identify further 
relevant manuscripts which may have been missed; 
 To provide feedback on the content of the guideline; 
 To provide judgement about indirectness of evidence; 
 To provide feedback on the draft recommendations; 
 To address additional concerns to be reported under a section on ‘other 
considerations’. 
2.3 Clinical research questions 
Among patients with suspicion of Birt-Hogg-Dubé syndrome or Familial 
atypical multiple mole melanoma syndrome or Neurofibromatosis 1 and 
neurofibromatosis 2, either based on symptoms or family history: 
 Who should undergo genetic testing? 
 What type of follow-up should patients undergo, depending on test 
results and diagnosis? 
2.4 General approach 
To verify if high-quality, recent guidelines are available that address the 
clinical research questions, a GCP project always starts with a search for 
guidelines. If such guidelines are available, the ADAPTE methodology is 
followed. 
If no high-quality, recent guidelines in line with the defined PICOs are 
available, the general approach will begin with the search for systematic 
reviews. 
For each research question a search for systematic reviews was conducted 
in MEDLINE, Embase and The Cochrane Library (Cochrane Database of 
Systematic Reviews, DARE and HTA database). If a recent high quality 
systematic review was available a search for primary studies published after 
the search date of the review were be performed in MEDLINE, Embase. If 
no systematic review is available a search for primary studies will be 
performed in those databases. Members of the guideline development group 
(GDG) will also be consulted to identify additional relevant evidence that 
may have been missed by the search. 
2.4.1 Study design 
 Inclusion criteria for the study design: 
o Diagnostic studies: systematic reviews, guidelines, meta-analyses, 
RCTs, prospective studies.  
 Articles in Dutch, English, French and German were included. 
 Exclusion criteria for study design: 
o Narrative reviews were only used for supplementary reference 
tracking; 
o Cadaver/animal studies;  
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o Case reports; 
o Studies presented as conference abstract only. If no full-text was 
available, the study was not taken into account for the final 
recommendations. 
 An iterative approach was followed: 
o First, the search focused on clinical guidelines of high quality; 
o Second, a search for recently published systematic reviews and 
meta-analyses (SR/MA) published after the search date of the 
selected clinical guidelines was performed; 
o Third, the selected evidence synthesis was updated by a search 
for all relevant primary studies (RCTs and prospective studies) 
published after the search date of the selected SR/MA. 
To be included, a systematic review had to: 
 address at least one of the research questions; 
 evaluate at least one of the selected (critical and important) outcomes; 
 search MEDLINE and at least one other electronic database; 
 include an assessment of risk of bias for each primary study. 
If more than one systematic review was identified for a particular research 
question, the focus was on the most complete systematic review. 
To be included a primary study had to:  
 be an RCT, a cohort study on the effectiveness of follow up, an 
observational study giving information on either prognostic value of an 
oncogenitic test or the validity of a set of testing criteria; 
 address at least one of the research questions; 
 evaluate at least one of the selected (critical and important) outcomes. 
2.4.2 Databases  
The following databases were included in the literature search:  
 The Cochrane Database of systematic reviews 
(http://www.cochrane.org) 
 Medline (http://www.ncbi.nlm.nih.gov/pubmed)  
 Embase (http://www.embase.com/) 
For the guidelines the search engines were:  
 National Guideline Clearinghouse http://www.guideline.gov/   
 G.I.N. guideline resource (http://www.g-i-n.net) 
Members of the GDG were also consulted to identify relevant evidence that 
might have been missed during the search process. 
2.4.3 Search strategy 
A combination of appropriate MeSH terms and free text words was used. 
The PICOs, the search strategy and number of publications retrieved 
corresponding to our research questions are documented in .  
Studies were screened on title and abstract. First, the titles and abstracts 
of the identified studies were checked and irrelevant studies were 
eliminated. In a second step, the remaining papers were screened by 
reading their full-text. If no full-text was available, the study was excluded 
for the final recommendations. Reference lists of the selected studies were 
hand searched for additional relevant manuscripts. 
The screening of the guidelines was performed on title and abstract. 
2.5 Quality appraisal 
2.5.1 Clinical practice guidelines 
We looked at the methodological quality of the identified international 
guidelines focusing on the questions if there was a documented search 
strategy and we evaluated the congruence between evidence and 
recommendations.  
2.5.2 Systematic reviews  
Selected (systematic) reviews were critically appraised by a single KCE 
expert. The AMSTAR checklist1 (http://amstar.ca/Amstar_Checklist.php) 
was used if it was a systematic review of interventions. In case of doubt, a 
second KCE expert was consulted. 
2.5.3 Primary articles 
Critical appraisal of each study was performed by a single KCE expert. In 
case of doubt, a second KCE expert was consulted. Details are described 
per syndrome. 
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2.6 Formulation of recommendations 
Based on the retrieved evidence, the first draft of recommendations was 
prepared by a small working group (KCE experts). This first draft was, 
together with the evidence tables, circulated to the guideline development 
group 2 weeks prior to the face-to-face meetings (15/09/2014 and 
18/11/2014). Recommendations were changed if important new evidence 
supported this change. Based on the discussion meetings a second draft of 
recommendations was prepared and once more circulated to the guideline 
development group for final approval.  
Due to current methodological limitations of the GRADE system for 
diagnostic tests, GRADE was not applied to the recommendations.  
2.7 External scientific validation 
As part of the standard KCE procedures, an external scientific validation of 
the report was conducted prior to its publication. The scientific content was 
assessed by 3 experts on 26th January 2015 (cf. names in the colophon).  
2.8 External review 
2.8.1 Healthcare professionals 
The recommendations prepared by the guideline development group and 
after scientific validation by the external validators were circulated to 
Professional Associations (Table 1). Each association was asked to assign 
one or two key representatives to act as external reviewers of the draft 
guideline. All expert referees made declarations of interest. 
Globally, 15 external experts were involved in the evaluation of the clinical 
recommendations and took part to the stakeholder meeting (10th February 
2015). All invited panellists received the scientific report for all research 
questions and were asked to score each recommendation indicating their 
agreement (or not) with the recommendation or to mention the topic was out 
of their research field. If panellists disagreed with the recommendation, they 
were asked to provide an explanation supported by appropriate evidence. 
Scientific arguments reported by these experts were used to adapt the 
formulation of the clinical recommendations. 
Table 1 – List of Professional Associations invited 
 College of Human Genetics 
 Belgian Society of Human Genetics 
 Belgian Society of Pathology 
 Belgian Society of Medical Oncology* 
 Belgian Society of Radiology  
 Royal Belgian Society of Dermatology and Venereology 
 Société Scientifique de Médecine Générale* 
* Representatives were assigned by these associations but did not join the meeting 
and did not send their evaluation form 
2.8.2 Patient representatives 
No specific patients associations exist in Belgium to specifically represent 
patients with the syndromes covered by these guidelines. However, two 
main associations support cancer patients to face with their disease and to 
accompany them (information, social actions to improve their quality of life). 
Both associations (Fondation contre le Cancer-Stichting tegen Kanker and 
Kom op tegen Kanker) were contacted to invite representatives to take part 
in the stakeholder meeting (10th February 2015).  
They were asked the following questions: 
 Have important considerations from a patients’ perspective been missed 
in the formulation of our recommendations? 
 Do we need to add information that could assist patients in making clear 
choices when doctors discuss treatment options with them? 
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3 BIRT-HOGG-DUBÉ SYNDROME 
3.1 Introduction 
Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant condition 
characterized clinically by skin fibrofolliculomas, pulmonary cysts, 
spontaneous pneumothorax, and renal cancer.2 In 2001, a BHD-associated 
gene locus was localized to chromosome 17p11 and truncating germline 
mutations were identified in the FLCN (BHD) gene, coding for a protein of 
unknown function called folliculin (FLCN).3, 4 
Its prevalence is estimated to be 1/200 000, based on a systematic search 
of the literature done by Orphanet, a consortium specialized in orphan drugs 
and rare diseases, but there may be underreporting.5 To date, approximately 
500 families have been reported worldwide according to the European Birt-
Hogg-Dubé Consortium (http://www.europeanbhdconsortium.eu). 
3.2 Search results 
Details of our search can be found in Appendix 1.1. 
We found 3 guidelines from which 2 were consensus based and did not have 
a formal search strategy.6, 7 In a third guideline, the BHD consortium put 
forward criteria for the diagnosis of BHD and criteria for testing. These 
recommendations are based on a literature search and expert opinion.2 An 
overall search strategy was provided but we could not find details on the 
search strategy they used nor on the relation between evidence and 
recommendations. 
We did not find studies that corresponded to our criteria, as we only found 
case reports and descriptions of data from registries of limited size with 
clinical descriptions and inventories of different mutations found on BHD 
patients, who were included from various sources and using variable 
inclusion criteria, clinical implications of these are therefore unclear.  
In what follows diagnostic criteria and testing criteria are proposed. 
Diagnostic criteria are the criteria that are used to decide if a patient has 
BHD syndrome.  Test results for FLCN are included in those criteria. Testing 
criteria on the contrary are criteria to decide what patients need to be 
referred for testing and counseling. The diagnostic criteria for BHD are part 
of those criteria. 
3.2.1 Diagnostic criteria for Birt-Hogg-Dubé syndrome  
The European Birt-Hogg-Dubé Consortium proposed criteria for BHD, 
largely based on expert opinion. 
Patients should fulfill one major or two minor criteria for diagnosis: 
Major criteria 
● At least five fibrofolliculomas or trichodiscomas, at least one 
histologically confirmed, of adult onset 
● Pathogenic FLCN germline mutation 
Minor criteria 
● Multiple lung cysts: bilateral basally located lung cysts with no other 
apparent cause, with or without spontaneous primary pneumothorax 
● Renal cancer: early onset (<50 years) or multifocal or bilateral renal 
cancer, or renal cancer of mixed chromophobe and oncocytic histology 
● A first-degree relative with BHD  
3.2.2 Criteria for referral to a genetic center and FLCN testing 
According the BHD consortium, all patients fulfilling the above mentioned 
diagnostic criteria should undergo genetic testing. However, BHD should 
also be considered in patients who do not fulfill the diagnostic criteria but still 
might have an underlying FLCN mutation.  
 Patients with early-onset renal cancer (<50 years), in particular with 
multifocal or bilateral disease (or both) with chromophobe or oncocytic 
histology. 
 Patients with unexplained cystic lung disease, pneumothorax, or both, 
especially if the lung cysts are bilateral and basally located.  
 Patients who have familial cystic lung disease, pneumothorax, familial 
renal cancer, or any combination of spontaneous pneumothorax and 
kidney cancer in an individual or family.  
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These recommendations however are largely based on expert opinion. 
There is not sufficient information from cohort studies nor validation studies 
to give a credible estimate of sensitivity, specificity or predictive value of 
these criteria. 
3.2.3 Management and follow-up 
The consortium recommends preventive measures largely aimed at early 
recognition and treatment of renal cancer. The optimum program for 
surveillance has not yet been established. 
They recommend to consider a yearly MRI scan of the kidney starting at age 
20 years. They also recommend to consider an assessment of lung 
involvement by thoracic CT scan before surgery that requires general 
anesthesia. 
These recommendations however are largely based on expert opinion. 
There is not sufficient information from cohort studies on the clinical benefit 
of surveillance.  
 
Other considerations 
Factor Comment 
Balance between clinical 
benefits and harms 
Patients with confirmed diagnosis may benefit from early diagnosis of renal cancer, however this remains unproven. 
The GDG considered that it was necessary to provide a statement on testing in underage patients. This was done based 
on the recommendations provided by American Society of Clinical Oncology (ASCO) and cited in gene reviews.8 Early 
detection of at-risk individuals affects medical management. However, in the absence of an increased risk of developing 
childhood malignancy, it is recommended to delay genetic testing in at-risk individuals until they reach age 18 years and 
are able to make informed decisions regarding genetic testing. 
The GDG found it necessary to put forward a recommendation to discourage scuba diving that is based on expert opinion, 
given the increased risk of pneumothorax among patients affected by BHD. 
Quality of evidence We only found case reports and descriptions of data from registries of limited size with clinical descriptions and 
inventories of different mutations found on BHD patients, who were included from various sources and using variable 
inclusion criteria, clinical implications are therefore unclear. We did not find studies on follow-up. Therefore, 
recommendations are largely consensus-based. KCE recommendations are based on the recommendations of the BHD 
consortium. The recommendations were slightly modified by the GDG at points where the GDG considered that the 
recommendations were not sufficiently clear, based on their expert opinion.  
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The GDG added ultrasound as a valid screening tool for renal cancer. They also found it necessary to specify that CT 
should be a high resolution CT. 
The consortium calls for further research, because the disease is rare and it will be difficult to collect evidence from 
studies with sufficient statistical power.  
Costs (resource allocation) Both BHD syndrome and conditions that cause BHD testing criteria to be fulfilled are rare, therefore it is likely that the 
impact of the recommendations on resource use is limited. 
The year of onset of renal cancer was lowered from 50 to 40 by the GDG, due to considerations on resource use. 
Patients values and preferences Due to the impact of such diagnosis on patients and their relatives, psychosocial support (how to deal with distress, how 
to deal with social issues ex. insurance, return to work etc.) should be offered to every patient during the entire process 
(before diagnosis, during testing and follow-up).  
 
Recommendations 
 Referral to a specialist genetics clinic for counselling and testing should be considered based on personal and family history, whether the individual is 
affected or not. 
 If possible, genetic testing for a family should usually start with the testing of an affected individual (mutation searching/screening) to try to identify a 
mutation in the appropriate gene. 
 Patients should be considered as a case of Birt-Hogg-Dubé syndrome if they fulfill one major or two minor criteria for diagnosis: 
Major criteria 
o At least five fibrofolliculomas or trichodiscomas, at least one histologically confirmed, of adult onset 
o Pathogenic FLCN germline mutation 
Minor criteria 
o Multiple lung cysts: bilateral basally located lung cysts with no other apparent cause, with or without spontaneous primary pneumothorax 
o Renal cancer in adults: early onset (<50 years) or multifocal or bilateral renal cancer, or renal cancer of mixed chromophobe and oncocytic histology. 
o A first-degree relative with BHD  
 
 Following patients should be referred for genetic testing and counseling: 
o Patients fulfilling the criteria for Birt-Hogg-Dubé syndrome mentioned above 
o Multifocal or bilateral renal cancer 
o Renal cancer of mixed chromophobe and oncocytic histology 
o Renal cancer onset below 40 with oncocytic histology 
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o Patients with unexplained cystic lung disease, and if the lung cysts are bilateral and basally located  
o Patients who have familial cystic lung disease, familial pneumothorax, familial renal cancer, or any combination of spontaneous pneumothorax and 
kidney cancer in an individual or family 
o A first-degree relative with BHD. 
 
 Early detection of at-risk individuals affects medical management. However, in the absence of an increased risk of developing childhood malignancy, it 
is recommended to delay predictive genetic testing in at-risk individuals until they reach age 18 years and are able to make informed decisions regarding 
genetic testing. 
For patients with confirmed BHD syndrome: 
 Consider a yearly MRI of the kidney starting at age 20 to 25 years; if the MRI is not conclusive a CT scan may be required. Ultrasound is appropriate for 
the follow-up of lesions but is less sensitive compared with MRI and CT for screening purposes. 
 Consider a low dose thoracic high resolution CT scan before surgery that requires general anaesthesia. 
 Discourage smoking and scuba diving. 
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4 FAMILIAL ATYPICAL MULTIPLE MOLE 
MELANOMA SYNDROME 
4.1 Introduction 
‘Familial atypical multiple mole melanoma (FAMMM) syndrome is an 
autosomal dominant genodermatosis characterized by multiple melanocytic 
nevi, usually more than 50, and a family history of melanoma. It is associated 
with mutations in the CDKN2A gene and shows reduced penetrance and 
variable expressivity. Some FAMMM kindreds show an increased risk for 
the development of pancreatic cancer and possibly other malignancies.’9 
Globally, 5 to 10% of malignant melanomas would occur in familial clusters 
but variations in penetrance and expressivity of the genes involved, regional 
variations and the fact that only limited data are available make it difficult to 
have an accurate estimate of the prevalence of FAMMM.10 
We found 2 guidelines that were consensus-based and did not have a formal 
search strategy.6, 7  
We did a search for primary studies and found a number of observational 
studies that corresponded to the criteria mentioned in 2.4.1 (details of our 
search can be found in 0). 
4.2 FAMMM criteria 
Melanoma Genetics Consortium, GenoMEL (www.genomel.org), an 
international research consortium publicly funded, published (on their 
website) consensus based criteria for families who require specialist 
counselling about risk: 
 Families with 2 first degree relatives with melanoma 
 Families with 2 cases (even if more distant relatives) if one or more have 
had multiple primaries or the cases have the atypical mole syndrome 
(dysplastic nevi) as self-examination is then rather more difficult 
 Families with 3 or more cases of melanoma 
This recommendation is based on prevalence studies of mutations in 
melanoma families. 
4.2.1 Prevalence of mutations in melanoma families and in the 
general population 
GenoMEL, comprising major familial melanoma research groups from North 
America, Europe, Asia and Australia included 466 families (2 137 patients) 
with at least three melanoma patients from 17 centers. They found that 
overall, 41% (n = 190) of families had mutations; most involved p16 (n = 
178). Mutations in CDK4 (n = 5) and ARF (n = 7) occurred at similar 
frequencies (2-3%). They found large differences in mutations across 
geographic locations.11 The proportion of families with CDKN2A mutations 
was highest in Europe (57%) where the baseline incidence of melanoma is 
relatively low, and lowest in Australia (20%), where the melanoma incidence 
is high. These differences are attributed to the fact that in regions of high 
melanoma incidence, such as Australia, there may be familial clustering of 
melanomas purely based on low-risk genes or statistical chance. This dilutes 
the apparent CDKN2A mutation rate. 
Berwick et al.12 showed that prevalence in first incident cases in the general 
population is much lower, around 1.2%.   
4.2.2 Risk of melanoma (penetrance) among CDKN2A mutation 
carriers in high risk families and families with population risk.  
Bishop et al.13 analysed 80 high risk (more than 3 melanoma cases) families 
containing 402 melanoma patients, 320 of whom were tested for mutations 
and 291 were mutation carriers. Overall, CDKN2A mutation penetrance was 
estimated to be 0.30 (95% confidence interval (CI) = 0.12 to 0.62) by age 50 
years and 0.67 (95% CI = 0.31 to 0.96) by age 80 years. By age 50 years 
CDKN2A mutation penetrance reached 0.13 in Europe, 0.50 in the United 
States, and 0.32 in Australia; by age 80 years it was 0.58 in Europe, 0.76 in 
the United States, and 0.91 in Australia.  
However, these estimates are only valid for multiple-case families. Orlow et 
al.14 showed in a population based study (n = 3 550) that the risk of 
melanoma in CDKN2A mutation carriers was approximately 14% (95% CI = 
8% to 22%) by age 50 years, 24% (95% CI = 15% to 34%) by age 70 years, 
and 28% (95% CI = 18% to 40%) by age 80 years. 
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4.2.3 Risk of other cancers 
An association of FAMMM with pancreatic cancers was shown in a number 
of studies. Goldstein et al.15 reported on a study done by the 17 GenoMEL 
groups (see above), on 385 families with ≥3 patients with melanoma. They 
found an association of pancreatic cancer with CDKN2A mutations in 
Europe and North America, but not in Australia. 
Desnoo et al.16 showed an increased risk of pancreatic cancer, cancer of the 
lip, mouth and pharynx, respiratory tumors, non-melanoma skin tumors, soft-
tissue tumours, and tumours of the eye/brain associated with CDKN2A 
founder mutation (p16-Leiden)-positive melanoma families. 
4.2.4 Interpretation of genetic tests within families affected by 
FAMMM 
FAMMM is associated with mutations in CDKN2A and CDK4. It is less clear 
however what the optimal interpretation and clinical implications of the test 
are within affected families. In the absence of these mutations the familial 
clustering is either caused by unknown susceptibility genes or the presence 
of a combination of low penetrance genes and/or other risk factors. It is 
unclear what the relative risk is of a member of a multiple case family where 
a susceptibility gene has been identified or where no susceptibility gene is 
identified. Moreover, within a family where a susceptibility gene is identified, 
the risk for individuals who happen to be tested negative, may remain higher 
than in the general population. 
4.3 Diagnostic work-up and follow-up of FAMMM 
There is only very limited evidence on the follow-up of FAMMM. No 
approach was ever tested in an RCT. Only a limited number of cohort studies 
were published. 
Vasen et al.17 screened nine families with the dysplastic nevus syndrome in 
the Leiden area (The Netherlands). A total of 50 primary melanomas were 
diagnosed in 38 persons. Nineteen of these melanomas had been 
diagnosed before the start of the screening programme (category I), 11 were 
detected at the initial examination of the families (category II), and 20 were 
found during the course of follow-up (category III). To assess the effect of 
screening, we compared these categories with respect to the developmental 
stage of the melanomas. One of the 19 melanomas in category I, two of the 
11 in category II and seven of the 20 in category III were melanoma in situ. 
The average thickness of the invasive melanomas in categories I, II and III 
was 1.75, 0.80 and 0.54 mm respectively. Sixteen of the 19 melanomas in 
category I (84%) were Clark III or IV, whereas 15 of the 20 melanomas in 
category III (75%) were Clark I or II. Effect on survival or morbidity remains 
to be proven. 
Hansson et al.18 reported on a program initiated in 1987 by the Swedish 
Melanoma Study Group where 2 080 individuals belonging to 280 melanoma 
families were followed for 14 years between 1987 and 2001 at 12 
participating centers. Among 1 912 skin lesions excised during follow-up, 41 
melanomas were removed in 32 individuals. Of these, 15 (37%) were in situ 
melanomas and 26 (63%) invasive melanomas. The median tumor 
thickness of invasive melanomas was 0.5 mm. Ulceration was absent in 24 
of 26 invasive melanomas (92%) and 12 (46%) lacked vertical growth phase. 
Compared with melanomas in the general Swedish population, the 
melanomas identified in these kindreds during follow-up had better 
prognostic characteristics. However, this may be due to lead time or 
overdiagnosis. Any effect on survival or morbidity remains to be proven.  
Hansson et al.18 documented a surveillance program using epiluminescence 
microscopy (ELM) and digital epiluminescence microscopy (DELM). High-
risk patients (n=212) were categorized by the number and phenotype of their 
naevi and their personal and family history of melanoma. Then patients were 
screened by the unaided eye, conventional photography, ELM and, in 
selected cases of atypia, DELM. Median follow-up was 18 months, and 
2 939 pigmented lesions were followed by DELM. Examination on the first 
visit identified 17 cutaneous melanomas. During the following observation 
period, another 17 melanomas were identified. Fifteen of these follow-up 
melanomas were exclusively identified based upon DELM. Clinical 
implications of these findings and to what degree DELM influences 
prognosis are unclear though. 
Skin Self Examination (SSE) has been advocated, but compliance could be 
a problem. Mesters et al.19 reported on 71 members of 18 FAMMM families 
where only 70% performed SSE at least once every 2-3 months. Adequate 
performers were more likely to have a partner, had a more positive attitude 
toward SSE, perceived SSE as less difficult to perform and had a stronger 
intention to perform SSE compared to poor performers. Logistic regression 
indicated attitude as the only reliable predictor of SSE performance. 
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No studies were performed on the effectiveness of screening for pancreatic 
cancer. 
4.4 Patient perception of counselling and testing - impact on 
behavior and distress levels 
Desnoo et al.20 found low levels of distress compared to the general 
population as measured by the Hospital Anxiety and Depression Scale 
(HADS) following counselling in both persons who took up the test and who 
did not among family members with a pre-test risk of being p16-Leiden 
mutation carriers of 50% or higher (melanoma patients and first degree 
relatives of melanoma or pancreas cancer patients). 
These low levels of anxiety were confirmed in a prospective follow up study 
by Aspinwall et al.21 among 60 high-risk patients in Utah (USA). 
Rieman et al.22 looked at the reasons to decline testing and found that a part 
of persons offered testing, categorized by the authors as ‘emotionally 
motivated respondents’ were hesitant to inform their family about an 
unfavorable test result and had unrealistic perceptions of what caused 
melanoma.  
Bergenmar et al.23 interviewed 11 consecutive members of families with 
CDKN2A mutation attending a pigmented lesion clinic at four occasions: 
before genetic testing, at disclosure of genetic test result and six months and 
one year after disclosure. The following areas were measured: anxiety and 
depression, risk perception, and sun-related habits. Disclosure of the test 
result did not seem to change family members' perception of their risk of 
developing melanoma. Few members reported anxiety of clinical 
significance and no one was depressed. Genetic testing of the members of 
melanoma families with CDKN2A mutations attending a pigmented lesion 
clinic did not appear to induce behavioral changes related to sun habits or 
emotional problems. 
Aspinwall et al.24 found that CDKN2A/p16 test reporting enhances 
compliance with early detection measures among CDKN2A/p16+ 
participants without diminishing the compliance of CDKN2A/p16- 
participants in high-risk patients in Utah (USA). This effect was confirmed 
after 2 years follow up.25, 26 
Bränström et al.27 gathered self-report data using online and paper-based 
surveys available in four languages among 312 individuals (62% from 
Europe, 18% from Australia, 13% from the USA and 7% from Israel). They 
found that participants were influenced by their phenotype and test results 
in risk estimations. Participants in the study expressed positive views on 
genetic research and towards genetic testing, but the study reported also 
that a non-informative (negative) test result might be associated with an 
(erroneous) perception of reduced risk and fewer preventive behaviours. 
Glanz et al.28 randomly assigned seventy-three adults with a family history 
of melanoma to be offered individualized CDKN2A and MC1R genotyping 
results in the context of a genetic counselling session, or the standard 
practice of not being offered counselling or disclosure of genotyping results. 
Participants in the intervention group reported an increase in the frequency 
of skin self-examinations compared with a slight decrease in the control 
group (p = 0.002). Participants in the intervention group reported a smaller 
decrease in frequency of wearing a shirt with long sleeves than did 
participants in the control group (p = 0.047). No effect of the intervention was 
noted for other outcomes. They concluded that feedback of CDKN2A and 
MC1R genotype among families without known pathogenic CDKN2A 
mutations does not seem to decrease sun protection behaviours. Because 
the study included only 3 individuals with deleterious mutations in the 
intervention group, these results provide relatively little insight into the effect 
of mutation testing on behaviors of individuals who test positive. However, 
they provide important evidence that genetic testing and counseling do not 
lead to false reassurance and reductions in sun protection behaviors among 
individuals who test negative. 
 
Conclusions 
● In multi-case (>2) families in Europe, 57% had CDKN2A mutations, but 
regional variability is high. In Belgium this frequency may be lower. 
● Risk of melanoma in CDKN2A positive members coming from multi-
case families varies by region. By age 50 years CDKN2A mutation 
penetrance reached 0.13 in Europe, 0.50 in the United States, and 0.32 
in Australia; by age 80 years it was 0.58 in Europe. 
● Risk of melanoma in CDKN2A positive persons coming from the general 
population is lower. 
● Members of FAMMM families have an increased risk of pancreatic 
cancer in Europe. 
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● Compared with melanomas in the general population, the melanomas 
identified in follow up programs have better prognostic characteristics. 
However, this may be due to lead time or over-diagnosis. Any effect on 
survival or morbidity remains to be proven. 
● There is no proof that screening for pancreatic cancer has a beneficial 
effect. 
● Evidence on the impact of offering counselling and testing, including 
counselling on sun protection, self-examination and compliance to 
screening is conflicting, with some studies showing indications of false 
reassurance and others an increased level of protective behaviour. 
● Counselling and testing is associated with low levels of distress. 
 
 
Other considerations 
Factor Comment 
Balance between clinical 
benefits and harms 
Benefit of genetic testing is controversial. As only 40 to 60% of FAMMM families test positive, a negative diagnosis in a 
family does not alter the need for enhanced surveillance and sun protection. A negative test in a family with a known 
mutation means a lower risk compared to a mutation positive family member but the risk may remain higher than the 
population risk and a negative test could give false reassurance. Therefore the Melanoma Genetics Consortium does not 
recommend systematic testing, but this position is controversial. 
Quality of evidence There is convincing proof from observational studies that there is an association between CDKN2A mutations and risk of 
melanoma, but prevalence of the mutations and risk of melanoma among carriers vary between regions and source of the 
mutation. When a mutation is found in a non FAMMM family member the risk is lower, indicating that other factors play a 
role explaining melanoma risk. Observational evidence shows that enhanced surveillance and follow up results in 
melanomas with better prognosis, but the role of lead time and over-diagnosis remains unclear. The effect on mortality or 
morbidity is unproven. Recommendations are therefore essentially based on expert opinion. 
Recommendations for follow up of patients are based on the consensus statement of the Melanoma Genetics Consortium 
Patients values and 
preferences 
The literature summarised above shows that some patients may be hesitant to inform family member of the test results 
but overall perception of testing and counselling is favourable.  
Due to the impact of such diagnosis on patients and their relatives, psychosocial support (how to deal with distress, how 
to deal with social issues ex. insurance, return to work etc.) should be offered to every patient during the entire process 
(before diagnosis, during testing and follow-up). 
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Recommendations 
 Consider a patient as FAMMM if all of the following criteria apply: 
o Malignant melanoma in one or more first- or second-degree relatives 
o High total body nevi count (often >50) including some of which are clinically atypical 
 
 Refer to a center for genetic counseling (preferably an affected member):  
o Families with 2 first degree relatives with melanoma 
o Families with 2 cases (even if more distant relatives) if one or more have had multiple primaries or the cases have the atypical mole syndrome 
(dysplastic nevi) as self-examination is then rather more difficult 
o Families with 3 or more cases of melanoma in the family (one of these cases may be pancreatic cancer) 
o Families with a patient with 3 or more primary melanoma 
 Testing should only be done after extensive counselling, including information on the limitations of genetic testing. 
Follow-up of members of a FAMMM family  
If you find a mutation in the family, carriers are considered at high risk and the following recommendations apply. Non-carriers in a known risk family may 
have an intermediate increased risk and should be managed as such. 
If you find no mutation then all members of the family should be considered to be at intermediate risk. 
 
The following recommendations can guide the follow-up of intermediate risk subjects together with the clinical judgment that takes into account the personal 
history of melanoma, the number of nevi, the presence of atypical nevi, and the family history.  
 
 Educate family members regarding the need for cutaneous photoprotection and the need to avoid sunburn, particularly in children; 
 Educate family members regarding pigmented lesion characteristics that suggest the presence of melanoma; 
 Perform a baseline, head-to-toe skin examination at age 12, and repeat every 6–12 months; 
 Perform monthly self-examination of the skin, seeking to identify new or changing pigmented lesions; 
 Consider supplementing skin cancer surveillance with (standardized) clinical photographs to facilitate recognizing clinically important pigmented lesion 
changes, especially in patients with numerous clinically atypical nevi; 
 Use dermoscopy (epiluminescence microscopy) and digital dermoscopy as an adjunct to evaluating pigmented lesions, particularly in high risk patients 
 Increase the frequency of skin examination during puberty and pregnancy, periods during which nevi may change rapidly; 
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 Excise all pigmented lesions that are clinically suggestive of melanoma as well as those that are changing in a clinically worrisome manner. Avoid 
wholesale, prophylactic removal of all nevi; 
 In CDKN2A mutation carriers consider offering the option to screen for pancreatic cancer through endoscopic ultrasound in combination with MRI if there 
is a first or second degree relative with pancreatic cancer. Explain there is no proven benefit. This can start at the age of 50 or 10 years younger than the 
earliest family member with pancreas cancer. As these tests are not currently considered standard of care, these patients should be included in clinical 
research screening programs if possible. 
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5 NEUROFIBROMATOSIS 1 
5.1 Introduction 
Neurofibromatosis type 1 is a relatively common inherited disorder that 
affects about one in 2 500 to one in 3 000 people worldwide, irrespective of 
sex or ethnic origin. Individuals with neurofibromatosis type 1 are prone to 
develop benign and malignant tumors of the central nervous system and 
peripheral nervous system, in addition to malignant diseases affecting other 
parts of the body. Tumors that are associated with the disorder include 
glomus tumor of the digits, glioma of the optic pathway, glioblastoma, 
malignant peripheral nerve sheath tumor, gastrointestinal stromal tumor, 
breast cancer, juvenile myelomonocytic leukemia (JMML), 
phaeochromocytoma, duodenal carcinoid tumor, and rhabdomyosarcoma.29 
We found 2 guidelines that were consensus based and did not have a formal 
search strategy.6, 7 These guidelines based themselves on the consensus 
guideline of the UK Neurofibromatosis Association.30 Members of the United 
Kingdom Neurofibromatosis Association Clinical Advisory Board 
collaborated to produce a consensus statement on the current guidelines for 
diagnosis and management of NF1.31 
We did a search for primary studies, details of our search can be found in 
Appendix 1.3. 
5.2 Diagnostic criteria 
The Consensus Development Conference proposed the name 
neurofibromatosis 1 and formulated the current diagnostic criteria, 
commonly indicated as the ‘National Institutes of Health (NIH) Diagnostic 
Criteria for neurofibromatosis 1’.32 
Two or more of the below criteria are required for diagnosis: 
 6 or more café au lait macules (>0.5 cm in children or >1.5 cm in adults) 
 2 or more cutaneous/subcutaneous neurofibromas or one plexiform 
neurofibroma 
 Axillary or groin freckling 
 Optic pathway glioma 
 2 or more Lisch nodules (iris hamartomas seen on slit lamp 
examination) 
 Bony dysplasia (sphenoid wing dysplasia, bowing of long bone ± 
pseudarthrosis) 
 First degree relative with NF1 
Early diagnosis is hampered by the fact that clinical signs appear at different 
times. Ferner et al. reviewed the clinical symptoms and the age of onset.33 
Common features as skin-fold freckling (85%) and Lisch nodules (>95%) 
appear after 3 years and cutaneous neurofibromas (>99%) appear after 7 
years and usually in the late teens.  
Debella et al.34 studied 1 893 NF1 patients under 21 years old from the 
National Neurofibromatosis Foundation International Database to determine 
the age at which the features included in the NIH Diagnostic Criteria appear. 
Approximately 46% of sporadic NF1 cases fail to meet the NIH Diagnostic 
Criteria by 1 year of age. Nearly all (97%; 95% confidence interval: 94-98) 
NF1 patients meet the criteria for diagnosis by the age of 8 years, and all do 
so by the age of 20 years. The usual order of appearance of the clinical 
features listed as NIH criteria is café-au-lait macules, axillary freckling, Lisch 
nodules, and neurofibromas. Symptomatic optic glioma is usually diagnosed 
by 3 years old, and characteristic osseous lesions are usually apparent 
within the first year of life. 
‘Legius syndrome presents as a mild neurofibromatosis type 1 (NF1) 
phenotype. Multiple café-au-lait spots and macrocephaly are present with or 
without axillary or inguinal freckling. Other typical NF1-associated features 
(Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas, 
and malignant peripheral nerve sheath tumors) are systematically absent.’35 
Messiaen et al.36 reported a pathogenic NF1 mutation was identified in 43% 
of sporadic cases (café-au-lait spots only with or without freckling and no 
other diagnostic criteria) and only in 1.3% a pathogenic SPRED1 mutation 
was found. In the cohort of familial cases with the same phenotypic criteria, 
73% carried a NF1 mutation and 19% a SPRED1 mutation.  
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5.3 Genetic testing 
Role of genetic testing in the diagnosis of NF1 is not assessed in formal 
validation studies, information comes mainly from reports of testing of series 
of patients fulfilling NF1 criteria to a variable degree. 
Messiaen et al.37 studied 67 unrelated NF1 patients fulfilling the NIH 
diagnostic criteria, 29 familial and 38 sporadic cases, using a cascade of 
complementary techniques. They identified the germline mutation in 64 of 
67 patients and 32 of the mutations were novel. 
Griffiths et al.38 studied 169 unrelated individuals suspected of having 
neurofibromatosis type I (NF1) over a 2 year period. Possible disease 
causing mutations were identified in 109 (64%) cases. These comprised 88 
different sequence alterations, of which 57 were novel. Out of the 169 cases 
referred, there were 102 patients with reliable clinical data, of whom 78 
satisfied the NIH diagnostic criteria for NF1. Within this cohort of NF1 
patients, NF1 mutations were identified in 61 individuals (78%). 
Valero et al.39 validated their genetic protocol for molecular diagnosis of NF1 
it in a cohort of 56 unrelated NF1 patients. All of the cases presented at least 
two diagnostic criteria for NF1. They identified a germline mutation in 53 
cases (95%), none of the three negative patients displayed a SPRED1-like 
phenotype. 
Sabbagh et al.40 did a comprehensive mutation analysis of 565 unrelated 
patients from the NF-France Network. A NF1 mutation was identified in 546 
of the 565 patients, this corresponds to a mutation detection rate of 97%. 
5.4 Diagnostic work-up and follow-up 
The optimal follow up of NF1 patients is based on expert opinion. The United 
Kingdom Neurofibromatosis Association Clinical Advisory Board31 made a 
consensus statement recommending regular annual visits and to record the 
following: 
 Development and progress at school 
 Visual symptoms, visual acuity and fundoscopy until age 7 years (optic 
pathway glioma*, glaucoma) 
 Head circumference (rapid increase might indicate tumour or 
hydrocephalus) 
 Height (abnormal pubertal development) 
 Weight (abnormal pubertal development) 
 Pubertal development (delayed/precocious puberty due to 
pituitary/hypothalamic lesion) 
 Blood pressure (consider renal artery stenosis, phaeochromocytoma) 
 Cardiovascular examination (congenital heart disease, especially 
pulmonary stenosis) 
 Evaluation of spine (scoliosis and/or underlying plexiform 
neurofibromas) 
 Evaluation of the skin (cutaneous, subcutaneous and plexiform 
neurofibromas) 
 System examination if specific symptoms 
They recommend visual assessment in young children because they do not 
complain of visual impairment. They also consider, given the high frequency 
of learning and behavioral problems in NF1 children, that monitoring is 
essential. Baseline brain and spine MRI, and routine imaging of the chest 
and abdomen to identify asymptomatic tumors, do not influence 
management and international guidelines discourage its use. 
 
Conclusions 
● NF1 mutations are found in 78 to 97% of cases fulfilling the consensus 
NF criteria.  
● Early diagnosis is hampered by the fact that clinical signs appear at 
different times. 
● There is a consensus that follow-up should be regular and focus on 
visual and cognitive impairment. 
● There is no proof that routine screening with imaging is helpful. 
● Part of the attenuated forms are caused by mutations in SPRED1 and 
may be undistinguishable from NF1 on clinical grounds. 
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Other considerations 
Factor Comment 
Balance between clinical 
benefits and harms 
Direct benefit of genetic testing for patients with a clear diagnosis is not clear, but can help with reproductive decisions. 
Testing is especially useful in cases of doubt, e.g. to distinguish NF1 and SPRED1 in attenuated forms. 
Quality of evidence We only have limited observational evidence on the presence of mutations among NF1 patients and prognostic 
evidence. Evidence is often difficult to interpret because testing is done on a subset of patients responding to certain 
criteria and not population based. Recommendations on follow up are essentially expert opinion based.  
Patients values and preferences Due to the impact of such diagnosis on patients and their relatives, psychosocial support (how to deal with distress, 
how to deal with social issues ex. insurance, return to work etc.) should be offered to every patient during the entire 
process (before diagnosis, during testing and follow-up). 
 
 
Recommendations 
 Diagnostic criteria: two or more of the below criteria are required for diagnosis: 
o 6 or more café au lait macules (>0.5 cm in children or >1.5 cm in adults) 
o 2 or more cutaneous/subcutaneous neurofibromas or one plexiform neurofibroma 
o Axillary or groin freckling 
o Optic pathway glioma 
o 2 or more Lisch nodules (iris hamartomas seen on slit lamp examination) 
o Bony dysplasia (sphenoid wing dysplasia, bowing of long bone ± pseudarthrosis) 
o First degree relative with NF1 
 
 Patients suspected with NF1 should be referred to a centre for genetic testing and counselling. 
 Testing after counselling should be considered especially in case of: 
o Unclear presentation that is suggestive but not sufficient to make the diagnosis of the syndrome 
o Incomplete presentation at an early age. 
o Reproductive decisions 
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 Patients presenting with multiple (6 or more according to the NIH) café-au-lait spots with or without axillary or inguinal freckling but no other NF1 related 
NIH criteria should be tested for NF1 first and if negative for SPRED1.  
 Genetic counselling prior to conception is advised in all NF1 individuals.  
 Children should be followed up every 6 to 12 months up to the age of 7 and annually until the age of 18. After the age of 18 they should be seen every 2 
to 3 years, The following should be recorded annually: 
o Development and progress at school 
o Visual symptoms, visual acuity and fundoscopy until age 7 years (optic pathway glioma, glaucoma) 
o Head circumference (rapid increase might indicate tumour or hydrocephalus) 
o Height (abnormal pubertal development) 
o Weight (abnormal pubertal development) 
o Pubertal development (delayed/precocious puberty due to pituitary/hypothalamic lesion) 
o Blood pressure (consider renal artery stenosis, phaeochromocytoma) 
o Cardiovascular examination (congenital heart disease, especially pulmonary stenosis) 
o Evaluation of spine (scoliosis ± underlying plexiform neurofibromas) 
o Evaluation of the skin (cutaneous, subcutaneous and plexiform neurofibromas) 
o System examination if specific symptoms 
 After the age of 18 they should be seen every 2 to 3 years at a specialised multidisciplinary NF1 clinic.  
 Blood pressure should be monitored regularly (at least annually).  
 Annual breast cancer screening should be done from 40 years on. 
 Patients should be instructed to consult if there is any rapid growth, pain, change in texture of a neurofibroma. 
 Patients with a NF1 microdeletion or a high volume of neurofibromas should be seen annually in specialised care to monitor for malignancies. 
 Preimplantation and prenatal diagnosis for neurofibromatosis can be offered. 
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6 NEUROFIBROMATOSIS 2 
‘Neurofibromatosis type 2 is a multiple neoplasia syndrome that results from 
a mutation in the NF2 tumour suppressor gene on chromosome 22q12. The 
disorder occurs in one in 25 000 live births and is inherited as an autosomal 
dominant trait. It has wide phenotypic variability and nearly 100% 
penetrance by 60 years of age. Improvements in diagnosis and treatment 
have led to a rise in the diagnostic prevalence from one in 210 000 in 1992, 
to one in 100 000 people in 2005.’41 
6.1  Diagnostic criteria 
We found 2 guidelines that were consensus based and did not have a formal 
search strategy.6, 7 These guidelines based themselves on the consensus 
guideline of the UK Neurofibromatosis Association.30 
We did a search for systematic reviews and primary studies, details can be 
found in Appendix 1.4 
Diagnostic criteria for NF2 were developed based on consensus, commonly 
referred to as the ‘Manchester criteria’ that are an expansion (additional 
criteria) of and include the NIH criteria. 
Bilateral vestibular schwannomas (VS) 
or family history of NF2 plus 
1. Unilateral vestibular schwannoma (VS) or 
2. Any two of: meningioma, glioma, neurofibroma, schwannoma, posterior 
subcapsular lenticular opacities 
Additional criteria:  
Unilateral VS plus any two of: meningioma, glioma, neurofibroma, 
schwannoma, and posterior subcapsular opacities 
Or 
Multiple meningioma (two or more) plus unilateral VS or any two of: glioma, 
neurofibroma, schwannoma, and cataract 
We found 2 validation studies on the diagnostic criteria in patients with no 
family history and without bilateral schwannomas (considered to be 
pathognomonic).  Both validation studies are based on the United Kingdom 
NF2 registry. We did not apply the QUADAS checklist for diagnostic tests as 
these are not classic validation studies for diagnostic test. We will discuss 
the possible biases of the studies instead. 
Baser et al.42 evaluated the Manchester criteria, the NIH criteria and the 
criteria of the national Neurofibromatosis Foundation (that are very similar 
to the Manchester criteria) on 163 of 403 people in the United Kingdom NF2 
registry (41%) who presented without bilateral vestibular schwannomas. 
The authors applied the sets of criteria to each person at initial assessment 
and at the most recent clinical evaluation (mean length of follow-up 13 
years). In people with "definite NF2" and a negative family history of NF2, 
the 1987 US NIH and 1991 NIH criteria each identify 78% of people at the 
most recent clinical evaluation but 0% at initial assessment. The National 
Neurofibromatosis Foundation (NNFF) criteria and the Manchester criteria 
each identify higher proportions at both time points (NNFF criteria, 91% and 
10%; Manchester criteria, 93% and 14%), but the proportions at initial 
assessment are still low. 
Main limitation of this study is the fact that recruitment in the registry is based 
on clinical suspicion and therefore entry into the database is not independent 
from the criteria, part or even most of the patients are tested precisely 
because they respond to a certain degree to some of the criteria that were 
evaluated. 
Baser et al.43 calculated the sensitivity and specificity of the Manchester 
criteria, the NIH criteria and the criteria of the national Neurofibromatosis 
Foundation based on 67 patients with definite NF2 and 142 who definitely 
do not have NF2 at the age of onset of the first characteristic sign of NF2. 
They found a sensitivity of 70% for the Manchester criteria, and lower 
sensitivities for the other sets of criteria. All sets had 100% specificity. Apart 
from the limitations related to the use of a registry, similar to the limitations 
mentioned for the first study, a case control design was used, with clearly 
defined cases and clearly defined controls. This design is known to lead to 
overestimation of both the sensitivity and specificity. They developed a 
scoring system (that they called themselves ‘Baser criteria’) that has 
sensitivity of 79 % (a 9 to 15 increase compared to existing sets of criteria) 
without loss of specificity (still 100 %) at age of onset of first symptom.  
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It weights symptoms before the age of 30 more, to address the problem of 
low sensitivity at age of onset. Development and validation were done in a 
case control design, independent validation is needed. Details of the scoring 
is given in Appendix 2.  
Hagel et al.44 suggested that the term “glioma” in the current diagnostic 
criteria for NF2 should be specified as “spinal ependymoma”. 
6.2 Follow-up 
The UK Neurofibromatosis Association has published consensus guidelines 
for the management of NF2. On the basis of expert opinion, they made 
following recommendations: 
 Children of affected patients should be considered to be at 50% risk of 
NF2. Ophthalmology examinations are recommended to begin at birth. 
Audiological examinations are suggested to start in early childhood. An 
annual full neurological examination is advised. 
 Gadolinium-enhanced magnetic resonance imaging (MRI) monitoring of 
the head and full spine, starting around age 10–12 years is 
recommended for all patients, as tumour growth may occur without 
symptoms. It may be sufficient to perform MRIs every other year up to 
age 20 and every 3 years thereafter for asymptomatic at-risk individuals 
without tumors. If tumors are present, MRIs should be conducted at least 
annually until the rates of tumour growth are established. 
We did not find studies on follow-up of patients. 
Conclusions 
● Manchester criteria seem highly specific but only moderately sensitive 
among patients without family history or bilateral schwannomas. 
Sensitivity is low at age of onset, as most criteria only become apparent 
over time. 
● A more sensitive scoring systems was developed but needs more 
independent validation. 
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Other considerations 
Factor Comment 
Balance between clinical 
benefits and harms 
Given the poor sensitivity of clinical diagnostic criteria and the debilitating nature of the disease, testing has a clear 
added value 
Quality of evidence  Two validation studies show that the Manchester criteria have good specificity but moderate to poor sensitivity, 
especially at onset of the symptoms. The studies suffer from several forms of bias. 
No studies assessing different follow up methods were found, recommendations are consensus based.   
Patients values and preferences Due to the impact of such diagnosis on patients and their relatives, psychosocial support (how to deal with distress, 
how to deal with social issues ex. insurance, return to work etc.) should be offered to every patient during the entire 
process (before diagnosis, during testing and follow-up). 
 
 
Recommendations 
 Patients suspected with NF2 should be referred to a centre for genetic testing and counselling. 
 Decision to test for NF2 should be based on clinical suspicion. Manchester criteria can provide a guidance but clinical judgment is needed especially with 
early manifestations, as the sensitivity of the Manchester criteria is low. 
Follow-up of NF2 patients should take place at a specialised multidisciplinary NF clinic: 
 Ophthalmological examinations are recommended to begin at birth. 
 Audiological examinations are suggested to start in early childhood.  
 An annual full neurological examination is advised. 
 Gadolinium-enhanced magnetic resonance imaging (MRI) monitoring of the head and full spine, starting around age 10–12 years, is recommended for all 
patients, as tumour growth may occur without symptoms. 
 It may be sufficient to perform MRIs every other year up to age 20 and every 3 years thereafter for asymptomatic at-risk individuals without tumours.  
 If tumours are present, MRIs should be conducted at least annually until the rates of tumour growth are established. 
 Prenatal preimplantation diagnosis should be discussed with the patient. 
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7 ADDITIONAL CONSIDERATIONS 
7.1 Adequate information and support for patients and 
relatives 
Genetic counselling, possibly followed by germline mutation analysis, has 
implications not only for the index person but also for his/her family. Hence, 
in addition to the medical aspects, patient preferences should be taken into 
account. Patients should be well and timely informed about all management 
options (surveillance and preventive treatment) and the advantages and 
disadvantages they offer. 
Patients’ representatives ask that a correct and understandable information 
be provided to individuals at increased genetic risk. Continued support in 
decision-making is important during the different phases of the process 
(referral, testing, steps after a positive or a negative test). It is important to 
clearly explain figures about the increased risk of (specific types of) cancer. 
Balanced and understandable information about the pros and cons of the 
various decisions has to be provided (e.g. about intensity of surveillance). 
There is a need for psychosocial support (by professionals and by fellow 
patients) when making choices, when informing children and family 
members about the genetic predisposition or with respect to fertility 
planning.  
7.2 Role of the genetic centres and the other professionals 
A uniform policy followed by all Genetic Centres in Belgium is essential. It is 
important that general practitioners / oncologists / dermatologists / 
psychologists are well informed about genetic mutations. 
7.3 Guideline update 
In view of the rapidly evolving evidence due to the dynamic nature of this 
field, the clinical introduction of the routine analysis of a broad panel of 
germline DNA in at risk subjects will be monitored by the authors. This 
guideline should be updated when sufficient clinical evidence is available. If, 
in the meantime, important new evidence would become available, this 
should be taken into consideration in the medical decision making.  
 
 
 28 Oncogenetic testing in BHD syndrome, FAMMM and Neurofibromatosis 1/2 KCE Report 243 
 
 APPENDICES 
APPENDIX 1. DETAILED SEARCH STRATEGIES 
Appendix 1.1. Birt-Hogg-Dubé syndrome 
Appendix 1.1.1. PICO 
Project number  
Project name Oncogenetic_testing_dermatology 
Search question(s)   Birt-Hogg-Dubé 
Structured search question(s) (PICO, SPICE, ECLIPSE, ..)  and related keywords 
P (patient) Suspected Birt-Hogg-Dubé  
I (Intervention) Genetic testing  
C (comparison) No testing  
O (outcome) any  
S (settings) any  
 
 KCE Report 243 Oncogenetic testing in BHD syndrome, FAMMM and Neurofibromatosis 1/2 29 
 
 
Appendix 1.1.2. Search strategies 
Date 2014-07-30 
Database  Medline (OVID) 
Search Strategy 
 
# Query Results 
1 exp genetic counseling/  11952 
2 exp Genetic testing/  26876 
3 exp DNA mutational analysis/  47423 
4 exp Heterozygote Detection/  8115 
5 exp Microarray Analysis/  75859 
6 (genet* adj3 (test* or screened or screening or detect* or assess* or profil* or 
counsel?ing)).tw.  
45982 
7 ((proteom* or genom* or gene? or sequence?) adj3 (screening or profil* or sequencing or 
screening or screened)).tw.  
74243 
8 (expression adj3 profil*).tw.  50610 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  263958 
10 Birt-Hogg-Dube Syndrome/  108 
11 (birt adj5 hogg adj5 dube).tw.  346 
12 fibrofolliculoma?.tw.  147 
13 trichodiscoma?.tw.  73 
14 acrochordon?.tw.  104 
15 12 and 13 and 14  25 
16 hornstein.tw.  13 
17 kickenberg.tw.  0 
18 "bhd syndrome".tw.  72 
19 10 or 11 or 15 or 16 or 17 or 18  375 
20 9 and 19  52 
Note  
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Date 2014-07-30 
Database  Embase (Embase.com) 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 'genetic screening'/exp 46,028 
#2 'genetic counseling'/exp 21,431 
#3 'nucleotide sequence'/exp 423,978 
#4 'heterozygote detection'/exp 5,882 
#5 'microarray analysis'/exp 39,450 
#6 (genet* NEAR/3 (test* OR screened OR screening OR detect* OR assess* OR profil* OR 
counseling OR counselling)):ab,ti 
58,604 
#7 ((proteom* OR genom* OR gene OR genes OR sequence OR sequences) NEAR/3 
(screening OR profil* OR sequencing OR screening OR screened)):ab,ti 
90,794 
#8 (expression NEAR/3 profil*):ab,ti 65,069 
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 633,109 
#10 'birt hogg dube syndrome'/exp 635 
#11 (birt NEAR/5 hogg):ab,ti 553 
#12 fibrofolliculoma:ab,ti OR fibrofolliculomas:ab,ti 246 
#13 trichodiscoma:ab,ti OR trichodiscomas:ab,ti 104 
#14 acrochordon:ab,ti OR acrochordons:ab,ti 135 
#15 #12 AND #13 AND #14 38 
#16 hornstein:ab,ti 23 
#17 kickenberg:ab,ti 0 
#18 'bhd syndrome':ab,ti 137 
#19 #10 OR #11 OR #15 OR #16 OR #17 OR #18 787 
#20 #9 AND #19 125 
Note  
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Date 2014-07-30 
Database  Cochrane 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 MeSH descriptor: [Birt-Hogg-Dube Syndrome] explode all trees 0 
#2 birt:ab,ti  1 
#3 hogg:ab,ti  7 
#4 dube:ab,ti  2 
#5 #2 and #3 and #4  1 
#6 fibrofolliculoma*:ab,ti  0 
#7 trichodiscoma*:ab,ti  0 
#8 acrochordon*:ab,ti  0 
#9 hornstein:ab,ti  1 
#10 kickenberg:ab,ti  0 
#11 "bhd syndrome":ab,ti  0 
#12 #1 or #5 or #9  2 
Note  
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Appendix 1.2. FAMMM 
Appendix 1.2.1. PICO 
Project number  
Project name Oncogenetic_testing_ 
Search question(s)   FAMM 
Structured search question(s) (PICO, SPICE, ECLIPSE, ..)  and related keywords 
P (patient) Suspected FAMMM  
I (Intervention) Genetic testing  
C (comparison) No testing  
O (outcome) any  
S (settings) any  
 
Appendix 1.2.2. Search strategies 
Date 2014-07-17 
Database  Medline (OVID) 
Search Strategy 
 
# Query Results 
1 fammm.tw.  61 
2 Dysplastic Nevus Syndrome/  990 
3 (familial adj3 melanoma?).ti,ab.  471 
4 ("B-K mole" adj3 (syndrome or melanoma)).ab,ti.  19 
5 1 or 2 or 3 or 4  1447 
6 exp Genetic testing/  26846 
7 exp genetic counseling/  11945 
8 exp DNA mutational analysis/  47377 
9 exp Heterozygote Detection/  8114 
10 exp Microarray Analysis/  75780 
11 6 or 7 or 8 or 9 or 10  159284 
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12 (genet* adj3 (test* or screened or screening or detect* or assess* or profil* or 
counsel?ing)).tw.  
45842 
13 ((proteom* or genom* or gene? or sequence?) adj3 (screening or profil* or sequencing or 
screening or screened)).tw.  
73883 
14 (expression adj3 profil*).tw.  50366 
15 12 or 13 or 14  139820 
16 11 or 15  263221 
17 5 and 16  115 
18 limit 17 to systematic reviews  2 
Note Results imported in endnote in 3 parts with automatic duplicates removal. 
Part 1: Systematic reviews (line 18) 2 results, no duplicates 
Part 2: genetic testing (line 17) 115 results, 4 duplicates removed 
Part 3: fammm all (line 5) 1447 results, 132 duplicates removed 
 
Date 2014-07-18 
Database  Embase (Embase.com) 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 'familial atypical multiple mole melanoma syndrome'/exp 102 
#2 'dysplastic nevus'/exp 1,854 
#3 familial:ab,ti OR multiple:ab,ti OR syndrome:ab,ti 1,858,111 
#4 #2 AND #3 516 
#5 #1 OR #4 609 
#6 fammm:ab,ti 76 
#7 (familial NEAR/3 melanoma*):ab,ti 566 
#8 ('b-k mole' NEAR/3 (syndrome OR melanoma*)):ab,ti 27 
#9 #5 OR #6 OR #7 OR #8 AND [embase]/lim 1,028 
#10 #5 OR #6 OR #7 OR #8 AND [medline]/lim AND [embase]/lim 765 
#11 #9 NOT #10 263 
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#12 'genetic screening'/exp 45,842 
#13 'genetic counseling'/exp 21,372 
#14 'nucleotide sequence'/exp 423,100 
#15 'heterozygote detection'/exp 5,879 
#16 'microarray analysis'/exp 39,287 
#17 #12 OR #13 OR #14 OR #15 OR #16 517,244 
#18 (genet* NEAR/3 (test* OR screened OR screening OR detect* OR assess* OR profil* OR 
counsel?ing)):ab,ti 
50,570 
#19 ((proteom* OR genom* OR gene OR genes OR sequence OR sequences) NEAR/3 
(screening OR profil* OR sequencing OR screening OR screened)):ab,ti 
90,472 
#20 (expression NEAR/3 profil*):ab,ti 64,854 
#21 #18 OR #19 OR #20 166,431 
#22 #17 OR #21 629,356 
#23 #11 AND #22 37 
Note Results imported in endnote in 2 parts with automatic duplicates removal. 
Part 1: fammm genetic testing (line 23) no duplicates discarded 
Part 2: fammm all (line 11) 263 results, 37 duplicates removed 
 
Date 2014-07-18 
Database  Cochrane 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 fammm:ti,ab,kw  0 
#2 MeSH descriptor: [Dysplastic Nevus Syndrome] explode all trees 6 
#3 (familial near/3 melanoma*):ti,ab  1 
#4 ("B-K mole" near/3 (syndrome or melanoma)):ti,ab  0 
#5 #1 or #2 or #3 or #4  7 
Note 7 results found in central, 1 title was relevant, after importation in Endnote, 5 duplicates were discarded including 
relevant one. 
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Appendix 1.3. Neurofibromatosis 1 
Appendix 1.3.1. PICO 
Project number  
Project name Oncogenetic_testing_ 
Search question(s)   Neurofibromatosis 1 
Structured search question(s) (PICO, SPICE, ECLIPSE, ..)  and related keywords 
P (patient) Suspected Neurofibromatosis 1  
I (Intervention) Genetic testing  
C (comparison) No testing  
O (outcome) any  
S (settings) any  
Appendix 1.3.2. Search strategies 
Date 2014-07-28 
Database  Medline (OVID) 
Search Strategy 
 
# Query Results 
1 Neurofibromatosis 1/  7584 
2 (neurofibromatos* adj3 ("1" or i)).tw.  4876 
3 recklinghausen*.tw.  2963 
4 (recklinghausen* adj3 disease).tw.  1995 
5 (watson adj2 syndrome).tw.  21 
6 nf1.tw.  3589 
7 "molluscum fibrosum".tw.  15 
8 ("cafe au lait" adj3 spot?).tw.  748 
9 2 or 3 or 4 or 5 or 6 or 7 or 8  9001 
10 1 or 9  11722 
11 exp Genetic testing/  26876 
12 exp genetic counseling/  11952 
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13 exp DNA mutational analysis/  47423 
14 exp Heterozygote Detection/  8115 
15 exp Microarray Analysis/  75859 
16 11 or 12 or 13 or 14 or 15  159440 
17 (genet* adj3 (test* or screened or screening or detect* or assess* or profil* or counsel?ing)).tw. 45962 
18 ((proteom* or genom* or gene? or sequence?) adj3 (screening or profil* or sequencing or 
screening or screened)).tw.  
74174 
19 (expression adj3 profil*).tw.  50561 
20 17 or 18 or 19  140326 
21 16 or 20  263850 
22 Genes, Neurofibromatosis 1/  746 
23 (test* or screened or screening or detect* or assess* or profil* or counsel?ing).tw.  5303412 
24 22 and 23  276 
25 10 and 21  719 
26 24 or 25  880 
27 limit 26 to systematic reviews  7 
28 neurofibromatoses/ 1545  
29 neurofibroma?.tw. 4348  
30 28 OR 29 5695 
31 21 AND 30 175 
32 31 NOT 26 37 
Note 7 results for systematic reviews 
880 results for all publications 
Line 32: Additional references using a more general MeSH but not specific to Neurofibromatosis type I. References were 
imported into a separate folder in EndNote file. 
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Date 2014-07-28 
Database  Embase (Embase.com) 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 'neurofibromatosis'/exp 16,058 
#2 (neurofibromatos* NEAR/3 (1 OR i OR peripheral)):ab,ti 5,950 
#3 recklinghausen*:ab,ti 3,568 
#4 (recklinghausen* NEAR/3 disease):ab,ti 2,388 
#5 (watson NEAR/3 syndrome):ab,ti 31 
#6 nf1:ab,ti 4,465 
#7 'molluscum fibrosum':ab,ti 8 
#8 ('cafe au lait' NEAR/3 (spot OR spots)):ab,ti 1,068 
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 19,065 
#10 'genetic screening'/exp 46,016 
#11 'genetic counseling'/exp 21,430 
#12 'nucleotide sequence'/exp 423,886 
#13 'heterozygote detection'/exp 5,881 
#14 'microarray analysis'/exp 39,433 
#15 #10 OR #11 OR #12 OR #13 OR #14 518,344 
#16 (genet* NEAR/3 (test* OR screened OR screening OR detect* OR assess* OR profil* OR 
counseling or counselling)):ab,ti 
58,587 
#17 ((proteom* OR genom* OR gene OR genes OR sequence OR sequences) NEAR/3 (screening 
OR profil* OR sequencing OR screening OR screened)):ab,ti 
90,765 
#18 (expression NEAR/3 profil*):ab,ti 65,051 
#19 #16 OR #17 OR #18 174,610 
#20 #15 OR #19 632,950 
#21 #9 AND #20 1,512 
#22 #21 AND [medline]/lim 1,116 
#23 #21 NOT #22 396 
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#24 #23 AND ([editorial]/lim OR [letter]/lim OR [note]/lim) 12 
#25 #23 NOT #24 384 
#26 #25 AND [animals]/lim NOT (#25 AND [humans]/lim) 8 
#27 #25 NOT #26 376 
#28 [cochrane review]/lim OR 'systematic review'/de OR 'meta analyse' OR [meta analysis]/lim OR 
[systematic review]/lim OR 'meta analyses' OR 'meta analysis'/de 
142,474 
#29 #27 AND #28 1 
Note  
 
Date 2014-07-28 
Database  Cochrane 
Search Strategy 
 
# Query Results 
#1 MeSH descriptor: [Neurofibromatosis 1] explode all trees 14 
#2 (neurofibromatos* near/3 ("1" or i or peripheral)):ti,ab  20 
#3 recklinghausen*:ti,ab  0 
#4 (recklinghausen* near/3 disease):ti,ab  0 
#5 (watson near/2 syndrome):ti,ab  0 
#6 nf1:ti,ab  18 
#7 "molluscum fibrosum":ti,ab  0 
#8 ("cafe au lait" near/3 (spot or spots)):ab,ti  1 
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8  25 
#10 MeSH descriptor: [Genetic Testing] explode all trees 487 
#11 MeSH descriptor: [Genetic Counseling] explode all trees 142 
#12 MeSH descriptor: [DNA Mutational Analysis] explode all trees 231 
#13 MeSH descriptor: [Heterozygote Detection] explode all trees 65 
#14 MeSH descriptor: [Microarray Analysis] explode all trees 268 
#15 #10 or #11 or #12 or #13 or #14  1040 
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#16 (genet* near/3 (test* or screened or screening or detect* or assess* or profil* or counselling or 
counseling)):ti,ab  
639 
#17 ((proteom* or genom* or gene or genes or sequence or sequences) near/3 (screening or profil* or 
sequencing or screening or screened)):ab,ti  
8584 
#18 (expression near/3 profil*):ti,ab  305 
#19 #16 or #17 or #18  9262 
#20 #15 or #19  9883 
#21 MeSH descriptor: [Genes, Neurofibromatosis 1] explode all trees 0 
#22 #9 and #20  0 
Note  
Appendix 1.4. Neurofibromatosis 2 
Appendix 1.4.1. PICO 
Project number  
Project name Oncogenetic_testing_ 
Search question(s)   Neurofibromatosis 2 
Structured search question(s) (PICO, SPICE, ECLIPSE, ..)  and related keywords 
P (patient) Suspected Neurofibromatosis 2  
I (Intervention) Genetic testing  
C (comparison) No testing  
O (outcome) any  
S (settings) any  
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Appendix 1.4.2. Search strategies 
Date 2014-07-28 
Database  Medline (OVID) 
Search Strategy 
 
# Query Results 
1 Neurofibromatosis 2/ 1083 
2 nf2.tw. 1359 
3 nf2s.tw. 3 
4 (neurofibromatos* adj ("2" or ii or central)).tw. 491 
5 ((neuroma? or schwannoma? or neurinoma?) adj5 acoustic adj5 (bilateral or familial)).tw 214 
6 2 or 3 or 4 or 5 1712 
7 1 or 6 2107 
8 Genes, Neurofibromatosis 2/ 420 
9 (test* or screened or screening or detect* or assess* or profil* or counsel?ing).tw. 5303412 
10 8 and 9 167 
11 exp Genetic testing/ 26876 
12 exp genetic counseling/ 11952 
13 exp DNA mutational analysis/ 47423 
14 exp Heterozygote Detection/ 8115 
15 exp Microarray Analysis/ 75859 
16 11 or 12 or 13 or 14 or 15 159440 
17 (genet* adj3 (test* or screened or screening or detect* or assess* or profil* or 
counsel?ing)).tw 
45962 
18 ((proteom* or genom* or gene? or sequence?) adj3 (screening or profil* or sequencing or 
screening or screened)).tw. 
74174 
19 (expression adj3 profil*).tw. 50561 
20 17 or 18 or 19 140326 
21 16 or 20 263850 
22 7 and 21 263 
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23 10 or 22 357 
24 limit 23 to systematic reviews 9 
Note  
 
Date 2014-07-28 
Database  Embase (Embase.com) 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 'neurofibromatosis'/exp 16,058 
#2 nf2:ab,ti 1,636 
#3 nf2s:ab,ti 3 
#4 (neurofibromatos* NEAR/2 (2 OR ii OR central)):ab,ti 1,958 
#5 ((neuroma OR neuromas OR schwannoma OR schwannomas OR neurinoma OR 
neurinomas) NEAR/5 acoustic):ab,ti AND (bilateral:ab,ti OR familial:ab,ti) 
413 
#6 #1 OR #2 OR #3 OR #4 OR #5 17,077 
#7 'genetic screening'/exp 46,016 
#8 'genetic counseling'/exp 21,430 
#9 'nucleotide sequence'/exp 423,886 
#10 'heterozygote detection'/exp 5,881 
#11 'microarray analysis'/exp 39,433 
#12 #10 OR #11 OR #12 OR #13 OR #14 518,344 
#13 (genet* NEAR/3 (test* OR screened OR screening OR detect* OR assess* OR profil* OR 
counseling or counselling)):ab,ti 
58,587 
#14 ((proteom* OR genom* OR gene OR genes OR sequence OR sequences) NEAR/3 
(screening OR profil* OR sequencing OR screening OR screened)):ab,ti 
90,765 
#15 (expression NEAR/3 profil*):ab,ti 65,051 
#16 #13 OR #14 OR #15 174,610 
#17 #15 OR #19 632,950 
#18 #17 AND #6 1,230 
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#19 #18 AND [medline]/lim 947 
#20 #18 NOT #19 283 
#21 #20 AND ([editorial]/lim OR [letter]/lim OR [note]/lim) 12 
#22 #20 NOT #21 271 
#23 #39 AND [animals]/lim NOT (#39 AND [humans]/lim) 7 
#24 #39 NOT #40 264 
#25 [cochrane review]/lim OR 'systematic review'/de OR 'meta analyse' OR [meta analysis]/lim 
OR [systematic review]/lim OR 'meta analyses' OR 'meta analysis'/de 
142,474 
#26 #24 AND #25 0 
Note    
 
Date 2014-07-28 
Database  Cochrane 
Search Strategy 
(attention, for PubMed, 
check « Details ») 
# Query Results 
#1 (neurofibromatos* near/3 ("2" or ii or central)):ti,ab  3 
#2 ((neuroma or neuromas or schwannoma or schwannomas or neurinoma or neurinomas) 
near/5 acoustic):ti,ab and (bilateral or familial):ti,ab  
0 
#3 nf2:ti,ab  1 
#4 nf2s:ti,ab  0 
#5 #1 or #2 or #3 or #4  3 
#6 MeSH descriptor: [Genetic Testing] explode all trees 487 
#7 MeSH descriptor: [Genetic Counseling] explode all trees 142 
#8 MeSH descriptor: [DNA Mutational Analysis] explode all trees 231 
#9 MeSH descriptor: [Heterozygote Detection] explode all trees 65 
#10 MeSH descriptor: [Microarray Analysis] explode all trees 268 
#11 #6 or #7 or #8 or #9 or #10  1040 
#12 (genet* near/3 (test* or screened or screening or detect* or assess* or profil* or counselling 
or counseling)):ti,ab  
639 
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#13 ((proteom* or genom* or gene or genes or sequence or sequences) near/3 (screening or 
profil* or sequencing or screening or screened)):ab,ti  
8584 
#14 (expression near/3 profil*):ti,ab  305 
#15 #12 or #13 or #14  9262 
#16 #11 or #15  9883 
#17 MeSH descriptor: [Neurofibromatosis 2] explode all trees 2 
#18 #5 or #17  4 
#19 #16 and #18  0 
Note    
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APPENDIX 2. BASER CRITERIA FOR DIAGNOSIS OF NF2 
 
Source: Baser et al.43 
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